Fisher & Paykel Healthcare Corp Ltd
FPH: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|.V# | LOCK|L@QB | LOCK|$&X%PQ^ |
Fisher & Paykel Healthcare: Tracking Better Than We Expected on Currency Tailwinds
Fisher & Paykel lifted its fiscal 2026 revenue and NPAT guidance by roughly 4% and 6%, respectively, due to a stronger New Zealand dollar. The year ending March 31 is tracking well, with Fisher expecting revenue of NZD 2.3 billion and NPAT of NZD 460 million, implying 14% and 22% growth.
